Pharmaceutical

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

December 1, 2025 Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals…

5 days ago

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 secondsWould potentially…

5 days ago

NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 – Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference

WILMINGTON, Del., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, the “Company”, “NRx”), a clinical-stage biopharmaceutical company…

5 days ago

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology…

5 days ago

Cerevance to Participate in RBC Capital Markets 2025 Healthcare Private Company Conference

BOSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment…

5 days ago

Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025

ROCKVILLE, Md. and SUZHOU, China, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage…

5 days ago

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study

Salarius subsidiary Decoy Therapeutics’ influenza fusion inhibitors, designed using its proprietary IMP3ACT™ platform, show excellent in silico free energy binding…

5 days ago

Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) --  Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused…

5 days ago

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025

Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ETSOUTH SAN FRANCISCO, Calif.…

5 days ago

Altimmune Announces CEO Transition and Succession Plan

Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong…

5 days ago